Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D2.430 - Two cases of acquired angioedema: one with splenic lymphoma and the other with Waldenström’s macroglobulinemia
D2.431 - Association of serum IgE levels and atopic status with cancer in the general population
D2.433 - AllergoOncology: Immunocompetent 3D and Skin Organoid Models of Melanoma to Investigate Tumour-Immune Interactions and Immunotherapies
D2.434 - AllergoOncology: Novel crusade for Basophil Activation Test
D2.432 - Blood morphology in health & cancer: comparative, preliminary study on 783 patients
D3.399 - Age-Dependent Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic esophagitis
D3.402 - Potential role of Advanced Glycation End-products in Pediatric Eosinophilic Esophagitis
D3.403 - Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study
D3.404 - Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent
D3.405 - Clinical Characteristics and Treatment Response of Eosinophilic Esophagitis in Pediatric Patients: A Descriptive Study from a High-Complexity Colombian Institution
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download